Next Article in Journal
Effects of Iron Oxide Nanoparticles (γ-Fe2O3) on Liver, Lung and Brain Proteomes following Sub-Acute Intranasal Exposure: A New Toxicological Assessment in Rat Model Using iTRAQ-Based Quantitative Proteomics
Previous Article in Journal
Microcirculatory Changes in Experimental Models of Stroke and CNS-Injury Induced Immunodepression
Open AccessArticle

Determination of the Pathological Features of NPC1 Variants in a Cellular Complementation Test

1
Translational Neurodegeneration Section „Albrecht-Kossel“, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany
2
Centogene AG, 18055 Rostock, Germany
3
Department of Medicine A, University Medicine Greifswald, 17489 Greifswald, Germany
4
Center for Transdisciplinary Neurosciences Rostock (CTNR), Rostock University Medical Center, University of Rostock, 18147 Rostock, Germany
5
German Center for Neurodegenerative Diseases (DZNE), Research side Rostock, 18147 Rostock, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(20), 5185; https://doi.org/10.3390/ijms20205185
Received: 3 September 2019 / Revised: 9 October 2019 / Accepted: 15 October 2019 / Published: 19 October 2019
(This article belongs to the Section Molecular Neurobiology)
Niemann-Pick Type C (NP-C) is a rare disorder of lipid metabolism caused by mutations within the NPC1 and NPC2 genes. NP-C is a neurovisceral disease leading to a heterogeneous, multisystemic spectrum of symptoms in those affected. Until now, there is no investigative tool to demonstrate the significance of single variants within the NPC genes. Hence, the aim of the study was to establish a test that allows for an objective assessment of the pathological potential of NPC1 gene variants. Chinese hamster ovary cells defective in the NPC1 gene accumulate cholesterol in lysosomal storage organelles. The cells were transfected with NPC1-GFP plasmid vectors carrying distinct sequence variants. Filipin staining was used to test for complementation of the phenotype. The known variant p.Ile1061Thr showed a significantly impaired cholesterol clearance after 12 and 24 h compared to the wild type. Among the investigated variants, p.Ser954Leu and p.Glu1273Lys showed decelerated cholesterol clearance as well. The remaining variants p.Gln60His, p.Val494Met, and p.Ile787Val showed a cholesterol clearance indistinguishable from wild type. Further, p.Ile1061Thr acquired an enhanced clearance ability upon 25-hydroxycholesterol treatment. We conclude that the variants that caused an abnormal clearance phenotype are highly likely to be of clinical relevance. Moreover, we present a system that can be utilized to screen for new drugs. View Full-Text
Keywords: variant of unknown significance; lipid metabolism; pharmacological chaperone; liver disease variant of unknown significance; lipid metabolism; pharmacological chaperone; liver disease
Show Figures

Figure 1

MDPI and ACS Style

Feng, X.; Cozma, C.; Pantoom, S.; Hund, C.; Iwanov, K.; Petters, J.; Völkner, C.; Bauer, C.; Vogel, F.; Bauer, P.; Weiss, F.U.; Lerch, M.M.; Knospe, A.-M.; Hermann, A.; Frech, M.J.; Luo, J.; Rolfs, A.; Lukas, J. Determination of the Pathological Features of NPC1 Variants in a Cellular Complementation Test. Int. J. Mol. Sci. 2019, 20, 5185.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop